v3.26.1
Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Apr. 30, 2026
Apr. 30, 2025
Apr. 30, 2026
Apr. 30, 2025
REVENUE        
Total revenue $ 179 $ 362 $ 630 $ 567
COSTS AND EXPENSES        
General and administrative 2,140 3,170 7,260 8,284
Research and development 4,853 3,003 16,866 5,276
Depreciation and amortization 48 62 153 238
Loss on impairment of goodwill 3,050
Loss from operations (6,870) (5,913) (23,678) (16,396)
Interest income 286 472 1,023 1,529
Realized gain on available-for-sale securities 178
Unrealized loss on investment - Cyclo (1,393) (5,144)
Unrealized (gain) loss on convertible notes receivable, due from Cyclo 383 (719)
Interest expense (6) (165) (327) (490)
Gain on settlement of accounts payable and convertible notes payable 3,723 3,958
Other income (loss), net (25) 154 54 74
Loss before income taxes (2,892) (6,462) (18,970) (20,968)
(Provision for) benefit from income taxes (6) 2,411 (52) 2,379
Consolidated net loss (2,898) (4,051) (19,022) (18,589)
Consolidated net loss (2,898) (4,051) (19,022) (18,589)
Net income (loss) attributable to noncontrolling interests 1,328 728 1,437 (163)
Net loss attributable to Rafael Holdings, Inc. (4,226) (4,779) (20,459) (18,426)
OTHER COMPREHENSIVE LOSS        
Consolidated net loss (2,898) (4,051) (19,022) (18,589)
Unrealized gain on available-for-sale securities 266 84 266 108
Foreign currency translation adjustment 24 4 110 37
Comprehensive loss (2,608) (3,963) (18,646) (18,444)
Comprehensive income (loss) attributable to noncontrolling interests 1,327 728 1,432 (165)
Comprehensive loss attributable to Rafael Holdings, Inc. $ (3,935) $ (4,691) $ (20,078) $ (18,279)
Loss per share attributable to common stockholders        
Basic (in Dollars per share) $ (0.08) $ (0.19) $ (0.4) $ (0.73)
Diluted (in Dollars per share) $ (0.08) $ (0.19) $ (0.4) $ (0.73)
Weighted average number of shares used in calculation of loss per share        
Basic (in Shares) 51,229,576 25,238,501 51,327,943 25,131,655
Diluted (in Shares) 51,229,576 25,238,501 51,327,943 25,131,655
Infusion Technology        
REVENUE        
Total revenue $ 42 $ 93
Rental – Third Party        
REVENUE        
Total revenue 60 49 173 147
Rental – Related Party        
REVENUE        
Total revenue 30 28 89 84
Cost of Product revenue        
REVENUE        
Total revenue 89 243 368 243
COSTS AND EXPENSES        
Cost of revenue 8 9 29 9
Cost of Infusion Technology revenue        
COSTS AND EXPENSES        
Cost of revenue $ 31 $ 106